In today’s Pharmaceutical Executive Daily, we cover Ypsomed’s new North Carolina manufacturing site, how pharma leaders are ...

The Most-Favored-Nation order requires U.S. drug prices to match or be lower than international prices, impacting domestic ...

Pre-clinical data supports ECRIs' broad-spectrum attack on the IgE axis, distinct from conventional anti-IgE therapies, ...

The pharmaceutical industry faces policy volatility with new tariffs, MFN pricing, and marketing rule changes, impacting ...

In discussing the evolving role of biotech CFOs, Hunter Smith emphasized that today’s finance leaders must act as the “voice of the investor,” ensuring disciplined capital allocation and long-term ...

In America, 80% of people on drugs are on generics. We talk a lot about pharma pricing, but the majority of people who are on multiple medications are on generics. For those drugs, you’re not going to ...

Regeneron's Libtayo gains FDA approval as the first immunotherapy for high-risk cutaneous squamous cell carcinoma, enhancing ...

In today’s Pharmaceutical Executive Daily, we explore why medical AI success depends on more than algorithms, Amgen’s launch ...

Bristol Myers Squibb (BMS) announced a definitive agreement in which BMS will acquire Orbital Therapeutics along with its ...

Shana Tetrault, PhD, Director of Product Marketing at Quanterix, discussed challenges in positioning Simoa in the precision ...

Novo Nordisk acquires Akero Therapeutics to enhance its portfolio with efruxifermin, a promising treatment for metabolic ...

Ypsomed invests $250 million in a new U.S. manufacturing facility, enhancing local supply and creating jobs in Holly Springs, ...